Form 4: PTC Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO Eric Pauwels sold 787 shares of PTC Therapeutics stock on April 17, 2024, to cover tax obligations related to vesting RSUs.
Summary
- On April 17, 2024, Eric Pauwels, the CEO of PTC Therapeutics, sold 787 shares of common stock.
- The sale was executed at a price of $25.135 per share.
- The transaction was conducted to cover tax withholding obligations associated with the vesting of 2,500 Restricted Stock Units (RSUs) from a grant made on April 16, 2020.
- Following the transaction, Pauwels directly owns 67,694 shares of PTC Therapeutics.
Sentiment
Score: 6
Explanation: The document describes a routine transaction (stock sale for tax obligations). It's neutral in sentiment as it doesn't inherently indicate positive or negative news about the company's performance or future prospects.
Industry Context
Executive stock sales for tax purposes are a common occurrence, especially around RSU vesting events. It's a standard practice and doesn't necessarily indicate a negative outlook on the company.
Key Dates
| Date | Description |
|---|---|
| 04/16/2020 | Date of the grant of 10,000 RSUs, part of which vested and triggered the tax obligations. |
| 04/17/2024 | Date of the stock sale transaction by Eric Pauwels. |
| 04/19/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.